LLY
757.36
+3.2%↑
JNJ
151.29
+1.18%↑
UNH
291.24
+6.59%↑
ABBV
183.96
+1.27%↑
NVO
64.34
-2.56%↓
LLY
757.36
+3.2%↑
JNJ
151.29
+1.18%↑
UNH
291.24
+6.59%↑
ABBV
183.96
+1.27%↑
NVO
64.34
-2.56%↓
LLY
757.36
+3.2%↑
JNJ
151.29
+1.18%↑
UNH
291.24
+6.59%↑
ABBV
183.96
+1.27%↑
NVO
64.34
-2.56%↓
LLY
757.36
+3.2%↑
JNJ
151.29
+1.18%↑
UNH
291.24
+6.59%↑
ABBV
183.96
+1.27%↑
NVO
64.34
-2.56%↓
LLY
757.36
+3.2%↑
JNJ
151.29
+1.18%↑
UNH
291.24
+6.59%↑
ABBV
183.96
+1.27%↑
NVO
64.34
-2.56%↓
24h
Current
Min
7.47
Max
7.98
Income | -41M -65M |
---|---|
Profit margin | -82.56 |
Recommendations | Strong Buy |
---|---|
12 Months Forecast | +90.54% upside |
Next Earnings | 6 sie 2025 |
---|
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
8 maj 2025, 19:14 UTC
Verastem Ovarian-Cancer Drug Combination Gets FDA Approval -- Update
DJ
Read
31 gru 2024, 19:15 UTC
Verastem Shares Soar on FDA Priority Review of Cancer Treatment
DJ
Read
Price change
By TipRanks
12 Months Forecast
Average 15.11 USD 90.54%
High 20 USD
Low 10 USD
Based on 9 Wall Street analysts offering 12 month price targets forVerastem Inc - Dist in the last 3 months.
By TipRanks
Strong Buy
9 ratings
9
Buy
0
Hold
0
Sell
Based on 9 analysts giving stock ratings to Verastem Inc - Dist in the past 3 months.
Selling and administration expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$